Veradigm extends stockholder rights plan to February 2026

Veradigm Inc. (OTCMKTS: MDRX) announced its board of directors approved an amendment extending the company's stockholder rights plan by six months to February 20, 2026.

The rights plan was originally adopted on February 26, 2024, and was scheduled to expire on August 20, 2025. The amendment also modified the triggering threshold, making rights exercisable only if a person or group acquires beneficial ownership of 20% or more of outstanding common stock shares in a transaction not approved by the board.

The board stated the extension is based on its determination that underlying risks and conditions present during the initial adoption continue to exist. The company said the rights plan does not prevent pursuing offers that are fair and in stockholders' best interests.

Veradigm indicated it intends to terminate the rights plan when the company becomes current in financial reporting and applies for relisting on a national stock exchange, which is expected to occur in 2026.

The healthcare technology company will file additional details about the amended rights plan in a Form 8-K with the Securities and Exchange Commission.

Veradigm provides healthcare data and technology solutions and operates the Veradigm Network, which serves healthcare provider, payer, and biopharma markets.

You May Also Be Interested In